Author Archive for Pharmboy

The Michael Pearson Era Is Officially Over: Valeant Appoints Joseph Papa As Chairman And CEO

Reminder: Ilene and Pharmboy are available to chat with Members, comments are found below each post.

Perrigo CEO Joseph Papa leaves Perrigo (PRGO) to lead Valeant (VRX) while PRGO issues a warning about missing earnings expectations. Not surprisingly, PRGO stock plummeted today. 

Robert Ingram, Chairman of the [Valeant] Board, stated, "The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time.  He has a strong shareholder orientation, a background in science, and an unmatched track record of accomplishments, highlighted by his ability to lead companies through times of transition and drive excellence across commercial, manufacturing and R&D platforms.  In addition, fostering an ethical culture and creating opportunities for professional development have always been high priorities for Joe, and we look forward to Joe's arrival at Valeant" (Valeant names Papa CEO after he resigns from Perrigo).

Reuters reports that Mr. Shareholder Orientation became "well-known on Wall Street last year when Dublin-based Perrigo rebuffed a $26 billion takeover by Mylan NV, the largest-ever hostile bid decided by a shareholder vote." Perrigo's market cap has now dropped to around $14.2 billion — down over 18% today alone -- making Papa look foolish for rejecting that buyout offer.

Papa’s departure comes just months after he successfully beat back a $26 billion hostile takeover bid from Mylan [MYL] spearheading a campaign that ultimately persuaded shareholders to reject Mylan’s bid.

Since then, though, Perrigo has reported disappointing quarterly results and slashed its outlook. (Perrigo shares tumble as CEO leaves for Valeant, guidance cut again)

Papa's recent record at PRGO reveals not only bad judgment but also, more disturbing, a lack of ordinary CEO loyalty. As Jim Cramer writes,

Perrigo's (PRGO) heartbreaking. How could Joe Papa, the man who was so intertwined with Perrigo for so long, the man who came on Mad Money and argued there was so much more value to the company than the price Mylan put on it — some 80 points higher than where it went out — just leave for Valeant (VRX)? How could he leave with a huge shortfall and some weird impairment charge about an acquisition that Papa crowed about, Omega, as a way to get international exposure?

There wasn't a single


continue reading





Perrigo: BTFD – Times Two?

Reminder: Ilene is available to chat with Members, comments are found below each post.

Update: PRGO may be losing its CEO to Valeant: Valeant’s Latest Acquisition Target: Perrigo’s CEO?. This news is knocking the price down into the low $120s. Paul says he is buying more shares and selling 2018 puts with a strike price of $150. See the screenshot below. Paul sold those three 2018 $150 puts.

Paul writes, "A forced change at the CEO level and PRGO’s depressed share price might induce management to reconsider its refusal to sell at above $200 when Mylan came calling last year. Shareholders are unhappy meaning something is likely being planned to get the stock moving again."

Updated chart:

As originally posted April 20, 2016. 

On June 10, 2015, Paul Price gave us a trade idea on BAX. Baxter Int. (BAX) was trading at around $66/share and scheduled to split off Baxalta (BXLT), its BioScience division, in the ratio of one share of BXLT for each share of BAX. BXLT is now at $40.65 and BAX is at $43.40. 

Baxter Int. (BAX) is splitting off its BioSciences division into a new company called Baxalta. Shares of Baxalta will be given as a tax-free dividend, in the ratio of one to one, to BAX holders on record on June 17, 2015. 

If you bought BAX, and held both companies after the split, till today, you'd have about a 27% gain. (Both Phil and Paul also suggested selling puts, see the article for more details.)

Now, for about a month, Paul's been suggesting buying and/or selling puts on Perrigo (PRGO, $129) at TheStreet.com's Real Money Pro (paywall) and Guru Focus. PRGO has been languishing around $128 – 130 and he thinks this area makes a good entry point for a longer term trade. Here are several excerpts from Paul's recent article at Real Money Pro with some updated charts. 

Healthcare products provider Perrigo (PRGO) has a fabulous long-term record. The stock dropped sharply on Feb. 18, 2016, as the firm took a charge in its latest quarter for costs associated with fighting off a hostile takeover attempt from Mylan (MYL). 


continue reading





Baxter’s Spinoff

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

Baxter Int. (BAX) is splitting off its BioSciences division into a new company called Baxalta. Shares of Baxalta will be given as a tax-free dividend, in the ratio of one to one, to BAX holders on record on June 17, 2015. That means, if you want to receive the Baxalta dividend, you need to buy the stock this week (on or before June 12).

The Baxalta Spinoff

By Ilene with Trevor of Lowenthal Capital Partners and Paul Price

In its recent filing with the SEC, Baxter provides:

“This information statement is being furnished in connection with the distribution by Baxter International Inc. (Baxter) to its shareholders of approximately 80.5% of the outstanding shares of common stock of Baxalta Incorporated (Baxalta), a wholly owned subsidiary of Baxter that will hold directly or indirectly the assets and liabilities associated with Baxter’s biopharmaceuticals business. To implement the distribution, Baxter will distribute approximately 80.5% of the shares of Baxalta common stock on a pro rata basis to the Baxter shareholders in a manner that is intended to be tax-free for U.S. federal income tax purposes.”

“As a result of the separation, each Baxter shareholder will receive one share of Baxalta common stock for every Baxter share of common stock held on June 17, 2015, the record date for the distribution.”

Trevor Lowenthal at Lowenthal Capital Partners, Paul Price and I have been reviewing Baxter and its upcoming spinoff of Baxalta. We believe that the spinoff will unleash value from the Baxalta bioscience division of the company and that the sum of the BAX parts will prove to be greater than the whole.  Baxalta should benefit from growing market penetration for Advate, the number one selling therapy in its hemophilia franchise, along with the approval of important new products. This should enhance long-term value for current BAX shareholders as Baxalta's new products hit the market and as the independent company gets priced more in line with its growth prospects. 

In April, Trevor Lowenthal shared his thoughts on BAX in Going Long On Baxter For An Optimistic 2016. To summarize:

  • Baxter has experienced several lackluster quarters, but the company's revenues are growing and its positive outlook


continue reading





Can Protalix BioTherapeutics Deliver?

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Here's an update on a stock that Pharmboy is well familiar with, PLX. Pharmboy provided his thoughts for this article which was published by Lowenthal Capital Partners, and which I contributed to them. One reader asked the question: While PLX has sufficient cash for another year's operation, it needs to conserve resources and will likely need to raise money in the future. Would you care to venture a guess as to when you believe they will raise money (and what type vehicle they will use)?

Pharmboy's response: They will sell stock, and my guess is in 4Q15. I agree--selling stock is probably on the horizon sooner rather than later. Let's hope they get the stock moving higher before then. ~ Ilene 

Can Protalix BioTherapeutics Deliver?

Protalix BioTherapeutics is a small biotech company that is working on developing clinically superior versions of recombinant therapeutic proteins for the treatment of genetic disorders, such as Gaucher's disease (GD) and Fabry disease (FD). It is based in Israel and was founded in 1993.

PLX is using its plant cell-based system, ProCellEx, to produce recombinant proteins with competitive advantages over existing recombinant protein therapies for indications that are known to be amenable to therapeutic protein replacement. The ProCellEx system is more robust and less expense than mammalian cell and yeast cell-based processes. Further, the ProCellEx system may produce biotherapeutics that can be delivered orally.

Currently, PLX has one recombinant therapeutic protein product on the market called taliglucerase alfa. Taliglucerase alfa is used for enzyme replacement therapy in Type 1 GD. It is being marketed with Pfizer (NYSE:PFE) under the brand name Elelyso.

PLX also has four potential recombinant protein drugs in early stages of development. PLX's active investigational programs address Gaucher's disease, Fabry disease, immune and inflammatory diseases such as inflammatory bowel disease, and cystic fibrosis.

While PLX has sufficient cash for another year's operation, it needs to conserve resources and will likely need to raise money in the future.

Given the comparative cost effectiveness and ease of use of ProCellEx in generating large quantities of therapeutic proteins, with the potential for effective oral delivery, I believe PLX is an interesting biotech speculation.


continue reading





Big Pharma’s Business Model is Changing

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Understanding the new normal of a business model is key to the success of any company.  The managment of companies need to adapt to the changing demand, but first they must recognize what changes are taking place.  Big Pharma's business model is changing rapidly, and much like the airline industry, there will be but a handful of pharma companies left at the end of this path.

Most Big Pharma companies have traditionally done everything from research and development (R&D) through to commercialisation themselves. Research was proprietary, and diseases were cherry picked on the back of academic research that was done using NIH grants.  This was in the heyday of research, where multiple companies had drugs for the same target (Mevocor, Zocor, Crestor, Lipitor), and could reap the rewards on multiple scales.  However, in the coming years, this research to commercialization model will no longer work for many organizations. If Big Pharma is to prosper, it will need to reduce costs while improving its R&D selectivity AND productivity.

The mid to late 1990s was the hayday of Big Pharma drug approvals.  Research was humming, treatments for diseases with large populations were rolling out, and pricing was favorable for reaping billions.  Big Pharma saw pharmacy benefit mangers as the wave of the future, as Pharma could sell their 'perferred' drugs through their networks, much like health insurance.  The bigger the PBM, the better off one would be, and Mevco (owned by Merck at the time), was growing rapidly!  Even if a drug was going generic, the PBM's would continue to sell the branded drugs for a premium, their own branded drugs!  All was good in the drug world.  Then the winds of change hit, where 2007/8 caused a backlash not only in the financial world, but also in pharma.  PBMs were sold off, as companies were accused of script manipulation and unfair pricing.  In addition, the margins were shrinking as the likes of TEVA, Dr. Reddy, and others were gaining market share.

Then, the 'Patent Cliff' started rearing its ugly head, and those big revenue streams were drying up.  In 2010, I wrote 'The Calm Before the Storm" article on PSW, noting that the for Big Pharma to continue, it needs…
continue reading





About Opko’s recent surge higher…

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

My friend Trevor at Lowenthal Capital Partners entitles his article on Opko Health (OPK) "Why Shorting Opko Health Makes No Sense After The Q1 2015 Earnings Report." So I asked him, "Why that title? Why not just say "Going Long OPK," or "OPK: Finally Earns Bubble Valuation, A Keeper!"? If you examine the key statistics, you will not fall in love with this stock. And one look at the chart explains Trevor's title. ~ Ilene

Six month chart (Yahoo)

But Trevor likes the shares, preferably a little cheaper, and explains why in his article, Why Shorting Opko Health Makes No Sense After The Q1 2015 Earnings Report

Excerpt:

Summary

  • Opko Health continues to impress on many fronts.
  • The Q1 2015 earnings report confirmed key developments related to 4Kscore Test reimbursement and NDA filing for Rayaldee, and the market is taking notice.
  • Management continues to buy shares on the open market. [Go to insider cow, look up OPK.]
  • For these reasons, shorting Opko Health does not seem to be a viable investment strategy.

[...]

I am a buyer of Opko at current price levels, as I believe there is considerable upside ahead. It seems that Opko is entering a period in which any number of developments could create shareholder optimism and spark a rally (which we are seeing now). And given the company's long-term growth potential looks strong, I do not believe establishing a short position in Opko is a viable investment strategy. Perhaps looking for short plays elsewhere in biotech is a safer bet.

There's truly been a lot of insider buying of Opko shares by the CEO indirectly as Frost Gamma Investments Trust. The chart below is from Insider Cow, the blue bars represent insider buying.  

 





2015 – Biotech Fever

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

PSW Members – well, what a year for biotechs!   The Biotech Index (IBB) is up a whopping 40%, beating the S&P hands down!  The healthcare sector has had a number of high flying IPOs, and beat the Tech Sector in total nubmer of IPOs in the past 12 months.  What could go wrong?

Phil has given his Secret Santa Inflation Hedges for 2015, and since I have been trying to keep my head above water between work, PSW, and baseball with my boys…it is time that something is put together for PSW on biotechs in 2015.

Cancer and fibrosis remain two of the hottest areas for VC backed biotechs to invest their monies.  A number of companies have gone IPO which have drugs/technologies that fight cancer, including JUNO Therapeutics (JUNO), Bellicum Pharmaceuticals (BLCM), Kite (KITE), Immune Design (IMDZ) in 2014.  On the other side, fibrosis can be a side effect of cancer as well as involved in a host of other diseases (IPF, NASH).  Fibrosis is less understood, and therefore can be harder to treat, and yet a number of high flying companies have been bought due to their drugs (GILD buying Arresto, Roche buying Intermune), and therefore fibrosis remains a very hot area.  One company in this space that just IPO'd is Fibrogen (FGEN). 

Cancer Company to Consider

JUNO Therapeutics (JUNO): Juno was founded on the backs of cancer researchers at Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute.  With more than $300M in funding, the stock IPO'd at 45% above its original midpoint, making it the year's second highest premium behind Castlight Health.  The company raised $265 million, giving it a >$2 billion valuation.  This made it the largest biotech IPO in at least 15 years both by deal size and market cap.  What Dendreon could have done had it picked the right cancer to use its techology!

JUNO's technology is chimeric antigen receptor, or CAR-t for short.  CAR-t technology is where the persons own T-cells (a white blood cell) are harvested and modified to fight cancer cells.  The technology has tested positive early…
continue reading





Biotechs & Bubbles

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Well PSW Subscribers….I am still here, barely.  From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired….buy a small amount.

First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices.  Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment.  Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer.  For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND  other drugs must often be used with it adding to the cost.  So, for more convenience and a better response rate….why not go for the best drug out there for HepC?  Other drugs are increasing in price, and the diagram below from Bloomberg shows that even Viagra has gone up in price considerably over the past 7 years.  Big pharma has infrastructure it needs to pay for, as well as investors that like outsized returns.  Biotechs, on the other hand, have drugs in clinic that can make or break the company.  Therefore, doing homework on these companies is critical, and understanding the science is imperative. 

The trend in industry (biotechs especially), is to go after the harder to treat diseases, which then also command a premium IF the drug is successful.  BMY bought Amira Pharmaceuticals for >$370M on the chance that their IPF drug (LPA1 receptor antagonist) works in these patients (life expectancy is 5 yrs).  Gilead bought Arresto for >$200M for the same indication (IPF), but a different mechanism of action (LOXL2 monoclonal antibody).  Both of these companies were finishing Phase 1…which means there was NO efficacy seen!!!  Intermune's drug Esbriet is expected to cost about $60k/yr, so if either of these drugs from BMY or GILD hit, and are better than Esbriet, then one can expect their prices to be higher!

So, which companies should be the focus? Well, one…
continue reading





Here We Go Again – Pharma & Biotechs 2014

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Ladies and Gentlemen, hobos and tramps,
Cross-eyed mosquitoes, and Bow-legged ants,
I come before you, To stand behind you,
To tell you something, I know nothing about.

And so the circus begins in Union Square, San Francisco for this weeks JP Morgan Healthcare Conference.  Will the momentum from 2013, which carried the S&P Spider Biotech ETF to all time highs, carry on in 2014?  The Biotech ETF beat the S&P by better than 3 points.

As I noted in my previous post, Biotechs Galore – IPOs and More, biotechs were rushing to IPOs so that venture capitalists could unwind their holdings (funds are usually 5-7 years), as well as take advantage of the opportune moment when the reward is all about risk.  In our current low interest rates environment, investors are starved for better returns, and the perfect place for those gains are high risk/reward biotechs.  A total of 46 companies went public in 2013 (16 more after my initial write-up), and 80% of them were ABOVE their IPO pricing!  The entire IPO 2013 class was up 48%!  48%! I know that cutting edge science is exciting, BUT when a company is valued for a potential treatment that still have a long way to go for final approval, I want to sell you a wing and a prayer for an idea I have that cures something I cannot tell you about….

Science is an exciting area to be apart of, and it is our hopes in this field to make an impact on a patient's life (for the better of course), but the gradiosity of the market sentiment for these biotechs makes me want to give everyone a Valium!  There is some very good science in the companies that went public, and those were covered in my previous post.  Now, a few more of those fledglings will be discussed.

Entana Pharmaceuticals (ENTA) – is riding the hepititis C wave that has engrossed the pharmaceutical industry the past few years.  Vertex (VRTX), Bristol (BMY), Merck (MRK), Gilead (GILD), JnJ (JNJ), and Abbvie (ABBV) are all in the space.  Even so, a few biotechs…
continue reading





Biotech Galore – IPOs and More

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Come and get it!  Read all about it! Biotechs, biotechs and more biotechs to buy buy buy for your portfolio! To date, almost 30 biotech companies have hit the market.  Most of the time, there are fewer than 10-12!

For the last five years, biotechs have had issues obtaining offer prices above expectations.  In 2013, that trend looks to be broken.  According to BiotechNow, the offer prices are 4% above expectations!  In addition, biotechs are going public with little more than a wing and a prayer (pre-clinical or Phase 1 data only).  Really? What this means is that the drug or technology looks good in mice, rats, or dogs, etc, but there is no smidgen of evidence that it will work in humans. That's what is called an appitite for RISK!

Of the thirty or so companies, several came out of the gate and have done quite well (figures from BiotechNow):

                        

Those are some impressive numbers, but what do the companies have that make them attractive?

Epizyme (EPZM) – One of the 'darling' companies of the IPO market, EPZM has moved into the heavens with its stock price, and a market cap of almost $1B for two Phase 1 programs that look very interesting, but have no validated human data.

The company is working on cancer, and more specifically histone methyltransferases (HMTs referred to hereafter).  This family of enzymes are involved in the winding and unwinding of DNA.  So, in cancer, if the specific enzyme that unwinds DNA is over expressed (more of it), then cancer cells can multiply faster.  EPZM is looking at two specific HMTs, DOT1L and EZH2. 

DOT1L inhibitor, EPZ-5676, is a small molecule inhibitor of created for the treatment of acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r). Due to the translocation, DOT1L is recruited to specific locations in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate methylation at these locations, which results in the increased expression of genes causing…
continue reading





 
 
 

ValueWalk

Louis Gave: In Three Years, China Won't Have Capital Controls Anymore

By Mauldin Economics. Originally published at ValueWalk.

Louis Gave, co-founder and CEO at Gavekal, is unequivocally bullish on China.

Speaking at the Strategic Investment Conference in Orlando, Florida, he stated his firm belief that China will soon open up its economic restrictions and become more accessible to investors worldwide.

Unsplash / PixabayReasons Behind China Capital Outflows

Asked about rumors of capital flight out of China into Western assets like Vancouver and Toronto real estate, Gave—who lives in Hong Kong—pointed out that there are several different reasons....



more from ValueWalk

Zero Hedge

Bitcoin Is Crashing

Courtesy of ZeroHedge. View original post here.

What goes up exponentially, falls vertically... or something like that...

Bitcoin has plunged 13% in the last few minutes... no catalyst evident for now...

However, in context, it's a fleshwound...

...

more from Tyler

Phil's Favorites

Fed Eyes Second Quarter Recovery, Expects Trump Fiscal Policy Will Expand Economy

Courtesy of Mish.

Data supporting the second quarter recovery thesis is nonexistent. Four out of four of the recent hard data economic reports have been negative.

Soft data diffusion indexes do not look so hot either.

Earlier today the Census Bureau reported the trade deficit widened. The same report shows retail and wholesale inventories declined by 0.3% each.

Advance Wholesale Inventories

Wholesale inventories for April, adjusted for seasonal variations but not for price changes, were estimated at an end-of-month level of $592.0 billion, down 0.3 percent (±0.4 percent)* from March 2017, and were up 1.8 perce...



more from Ilene

Market News

News You Can Use From Phil's Stock World

 

Financial Markets and Economy

OPEC Boss Embraces Shift to Top Diplomat (The Wall Street Journal)

During a turbulent year for oil prices, the Organization of the Petroleum Exporting Countries’ top official, Mohammad Barkindo, has embraced a role as the global energy industry’s chief diplomat.

Eurozone ‘still fragile’ despite growth spurt, warns European Central Bank (The Telegraph)

Europe’s sovereign debt crisis might seem like a distant memory as the eurozone economy ...



more from Paul

Chart School

Gold supply and demand battle near resolution

Courtesy of Read the Ticker.

Energy builds up during a long slow sideways pattern which allow money managers to accumulate or distribute float, very soon either the demand or supply side is going to get knocked out. Soon we well have a winner! Both the moving averages and Gann angles show the tight APEX, a break out either way will happen. Our bias is to the upside.

If you review a hand full of gold stocks (say ABX, NEM, GG, HMY) you can see higher lows, and consolidations tightening after a period of volatility, this means those that wish to sell from the recent rally have done so, there done! Now the time for the next move is very near. The good news is that most big money managers missed the 2016 rally, and they are getting ready for the next move higher (we believe).

...

more from Chart School

Members' Corner

Robert Sapolsky: The biology of our best and worst selves

Interesting discussion of what affects our behavior. 

Description: "How can humans be so compassionate and altruistic — and also so brutal and violent? To understand why we do what we do, neuroscientist Robert Sapolsky looks at extreme context, examining actions on timescales from seconds to millions of years before they occurred. In this fascinating talk, he shares his cutting edge research into the biology that drives our worst and best behaviors."

Robert Sapolsky: The biology of our best and worst selves

Filmed April 2017 at TED 2017

 

p.s. Roger (on Facebook) saw this talk and recommends the book ...



more from Our Members

OpTrader

Swing trading portfolio - week of May 22nd, 2017

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Digital Currencies

Bitcoin Soars Above $2000 For First Time Ever

Courtesy of Zero Hedge

Bitcoin is now up over 100% in 2017, amid global political uncertainty and increased interest in Asia, suddenly spiking above $2000 this afternoon for the first time ever...

That is a year-over-year gain of more than 350%. The move comes, as CoinDesk notes, amid a broader boost in the cryptocurrency market, which broke the $60bn barrier today. The increase has taken place amid strong surges from Ripple's XRP, which seeks to lower costs in enterprise cross-border payments, and ethereum's ether token, a cryptographic asse...



more from Bitcoin

Biotech

Beyond just promise, CRISPR is delivering in the lab today

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Beyond just promise, CRISPR is delivering in the lab today

Courtesy of Ian HaydonUniversity of Washington

Precision editing DNA allows for some amazing applications. Ian Haydon, CC BY-ND

There’s a revolution happening in biology, and its name is CRISPR.

CRISPR (pronounced “crisper”) is a powerful technique for editing DNA. It has received an enormous amount of attention in the scientific and popular press, largely based on the promise of what this powerful gene e...



more from Biotech

Kimble Charting Solutions

Brazil; Waterfall in prices starting? Impact U.S.?

Courtesy of Chris Kimble.

Below looks at the Brazil ETF (EWZ) over the last decade. The rally over the past year has it facing a critical level, from a Power of the Pattern perspective.

CLICK ON CHART TO ENLARGE

EWZ is facing dual resistance at (1), while in a 9-year down trend of lower highs and lower lows. The counter trend rally over the past 17-months has it testing key falling resistance. Did the counter trend reflation rally just end at dual resistance???

If EWZ b...



more from Kimble C.S.

Mapping The Market

Bombing - Right or Wrong?

Courtesy of Jean-Luc

I am telling you Angel – makes no sense… BTW:

Republicans Love Bombing, But Only When a Republican Does It

By Kevin Drum, Mother Jones

A few days ago I noted that Republican views of the economy changed dramatically when Donald Trump was elected, but Democratic views stayed pretty stable. Apparently Republicans view the economy through a partisan lens but Democrats don't.

Are there other examples of this? Yes indeed. Jeff Stein points to polling data about air strikes against Syria:

Democr...



more from M.T.M.

Promotions

Free eBook - "My Top Strategies for 2017"

 

 

Here's a free ebook for you to check out! 

Phil has a chapter in a newly-released eBook that we think you’ll enjoy.

In My Top Strategies for 2017, Phil's chapter is Secret Santa’s Inflation Hedges for 2017.

This chapter isn’t about risk or leverage. Phil present a few smart, practical ideas you can use as a hedge against inflation as well as hedging strategies designed to assist you in staying ahead of the markets.

Some other great content in this free eBook includes:

 

·       How 2017 Will Affect Oil, the US Dollar and the European Union

...

more from Promotions

All About Trends

Mid-Day Update

Reminder: Harlan is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David



FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>